Next, we correlated CACNA1B (Cav2.2) protein expression with NSCLC patients' clinical characteristics, including gender, age at diagnosis, tumor size, histopathology grading, lymph node metastasis, smoking history, and TNM stage. Here, CACNA1B is linked to metastatic malignant neoplasm in the lymph nodes.